News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
It is a novel oral NLRP3 inflammasome inhibitor
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The fund aims at investing in companies that extends human healthspan
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
